Prescription psychotropic medication use among the U.S. adult population: results from the third National Health and Nutrition Examination Survey, 1988–1994

Paulose-Ram, Ryne; Jonas, Bruce S.; Orwig, Denise; Safran, Marc A.

doi:10.1016/j.jclinepi.2003.05.001

Cited by 71 publications

(88 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, evidence on the association between AX-HY use and socioeconomic groups remains still contradictory [56][57][58][59][60]. Consequently, our results cannot be considered as representative of the regional population as a whole.…”

Section: Discussionmentioning

confidence: 77%

Dispensing of anxiolytics and hypnotics in southeastern France: demographic factors and determinants of geographic variations

Bocquier

Bezzou

Nauleau³

et al. 2008

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

We examined geographic variations in the dispensing of anxiolytics and hypnotics (AX‐HY) and their determinants at the canton level in southeastern France. Data were collected from the 2005 outpatient database of the Southeastern France General Health Insurance Fund, covering more than 70% of the population. We calculated the annual age‐adjusted prevalence rates of subjects filling prescriptions for AX‐HY at least once (to measure ‘overall use’) and at least six times (‘chronic use’), assessed geographic variations with the extremal quotient and weighted coefficient of variation, and conducted simple and multiple linear regression analysis to study their determinants. Prevalence rates of overall and chronic AX‐HY use were 15.5% and 5.9%, respectively, and varied significantly between cantons, by a factor of 3–4. The prevalence of mental illness and that of chronic illness were independently and positively associated with overall and chronic use; unemployment rates and mean family income were positively associated only with overall use. Density of general practitioners did not explain geographic variations. These results provide a basis for targeting interventions to reduce AX‐HY use and promoting appropriate discontinuation. Future studies should examine trends in those geographic variations.

show abstract

Section: Discussionmentioning

confidence: 77%

Dispensing of anxiolytics and hypnotics in southeastern France: demographic factors and determinants of geographic variations

Bocquier

Bezzou

Nauleau³

et al. 2008

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Although the NHANES-III examined American psychotropic medication use between 1988 and 1994, there has been no American nationally representative drug utilization survey reported since then (2).…”

mentioning

confidence: 99%

Psychotropic Medication Use in Canada

et al. 2005

View full text Add to dashboard Cite

Background: Psychotropic medication use can be employed as an indicator of appropriate treatment for mental disorders. The Canadian Community Health Survey: Mental Health and Well-Being (CCHS 1.2) offers the first opportunity to characterize Canadian psychotropic medication use on a national level within diagnostic groups as assessed by a full version of the Composite International Diagnostic Interview (CIDI). Method: We assessed the prevalence of antidepressant, sedative-hypnotic, mood stabilizer, psychostimulant, and antipsychotic use over 2 days overall and in subgroups defined by CIDI-diagnosed disorders and demographics. We employed sampling weights and bootstrap methods. Results: Overall psychotropic drug utilization was 7.2%. Utilization was higher for women and with increasing age. With any lifetime CIDI-diagnosed disorder assessed in the CCHS 1.2, utilization was 19.3%, whereas without such disorders, it was 4.1%. Selective serotonin reuptake inhibitors (SSRIs) were the most commonly used antidepressants for those with a past-year major depressive episode (17.8%), followed by venlafaxine (7.4%). Among people aged 15 to 19 years, antidepressant use was 1.8% overall and 11.7% among those with past-year depression; SSRIs made up the majority of use. Sedative-hypnotics were used by 3.1% overall, increasing with age to 11.1% over 75 years. Conclusions: International comparison is difficult because of different evaluation methods, but antidepressant use may be higher and antipsychotic use lower in Canada than in recent European and American reports. In light of the relative lack of contemporary evidence for antidepressant efficacy in adolescents, it is likely that antidepressant use among those aged 15 to 19 years will continue to decline. The increased use of sedative-hypnotics with age is of concern, given the associated risk of adverse effects among seniors.

show abstract

“…n = Number of patients that could be evaluated. 1 Including zolpidem and zopiclone. 2 The possible range of scores in the domain, with 0 meaning no impact/interference and 100 meaning maximum interference/ impact, or vice versa in case of adequacy of sleep, are shown in parentheses.…”

Section: Study Participantsmentioning

confidence: 99%

“…Correlation coefficients were significant at p < 0.05 in all cases except 'snoring' with BWSQ, which was not significant. 1 The possible range of scores in the domain with 0 meaning no impact/interference and 100 meaning maximum interference/ impact, or vice versa in the case of adequacy of sleep, is shown in parentheses.…”

Section: Pregabalin As a Tapering Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Pregabalin on Subjective Sleep Disturbance Symptoms during Withdrawal from Long-Term Benzodiazepine Use

Rubio

Bobes²,

Cervera³

et al. 2011

Eur Addict Res

View full text Add to dashboard Cite

Aim: To evaluate the effectiveness of pregabalin as a tapering therapy on the subjective sleep quality of patients who underwent a benzodiazepine withdrawal program in routine medical practice. Methods: Secondary analysis of a 12-week prospective, open noncontrolled study carried out in patients who met DSM-IV-TR criteria for benzodiazepine dependence. Sleep was evaluated with the Medical Outcomes Study Sleep Scale (MOS Sleep Scale). Results: 282 patients were included in the analysis. Mean (±SD) pregabalin dose was 315 ± 166 mg/day at the end of the trial. We observed a significant and clinically relevant improvement in sleep outcomes at the endpoint, with a total score reduction from 55.8 ± 18.9 to 25.1 ± 18.0 at week 12 (i.e. a 55% reduction). Similar findings were apparent using the six dimensions of the MOS Sleep Scale. Moderate correlations were observed between the MOS Sleep summary index and sleep domains, and there were improvements in anxiety symptoms and disease severity. Conclusions: These findings suggest that pregabalin may improve subjective sleep quality in patients who underwent a benzodiazepine withdrawal program. This effect appears to be partly independent of improvements in symptoms of anxiety or withdrawal. However, controlled studies are needed to establish the magnitude of the effect of pregabalin.

show abstract

Prescription psychotropic medication use among the U.S. adult population: results from the third National Health and Nutrition Examination Survey, 1988–1994

Cited by 71 publications

References 31 publications

Dispensing of anxiolytics and hypnotics in southeastern France: demographic factors and determinants of geographic variations

Dispensing of anxiolytics and hypnotics in southeastern France: demographic factors and determinants of geographic variations

Psychotropic Medication Use in Canada

Effects of Pregabalin on Subjective Sleep Disturbance Symptoms during Withdrawal from Long-Term Benzodiazepine Use

Contact Info

Product

Resources

About